Coltuximab ravtansine

Drug Profile

Coltuximab ravtansine

Alternative Names: Anti-CD19-DM4 immunoconjugate SAR3419; huB4-DM4; Maytansin-loaded anti-CD19 mAb; SAR-3419

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmunoGen
  • Class Antineoplastics; Immunoconjugates; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Diffuse large B cell lymphoma

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma
  • Discontinued Acute lymphoblastic leukaemia

Most Recent Events

  • 30 Sep 2016 Coltuximab ravtansine is available for licensing as of 30 Sep 2016.
  • 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
  • 27 Jun 2015 Coltuximab ravtansine is still in phase II trials for Diffuse large B-cell lymphoma in Belgium, Czech Republic, Italy, Poland, Spain and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top